Latest / Pharmacy Podcast Network / Pharmacists leading in Pharmacovigilance & Hormone Therapies | TWIRx
Transcript
- 0:00Speaker 1: Hey, and on this Week in Pharmacy, powerful episode spotlighting
- 0:05Speaker 1: the critical leadership roles pharmacists are taking in two vital
- 0:09Speaker 1: areas of patient care, pharmacovigilance and hormone replacement therapy and
- 0:14Speaker 1: treatment therapies with doctor Sarah Rodgers and doctor Tiffany Ruter.
- 0:21Speaker 2: You're not going to want to miss this Week in Pharmacy.
- 0:41Speaker 1: Hey, and on this Week in Pharmacy, did you know
- 0:44Speaker 1: that it's National Adverse Drug Event Awareness Day just passed
- 0:49Speaker 1: this week? I think it was on the twenty fourth
- 0:52Speaker 1: of March. And how important that is.
- 0:54Speaker 2: That's right.
- 0:55Speaker 1: This is TWERKS zero three, twenty eight to twenty five.
- 1:00Speaker 1: It has been a busy week. Just got back from
- 1:02Speaker 1: Nashville from the American Pharmacist Association twenty twenty five. That
- 1:07Speaker 1: was a super Bowl event for us. It was amazing.
- 1:10Speaker 1: Please be on the lookout for that three part series
- 1:13Speaker 1: that will be coming out starting I think late next week.
- 1:17Speaker 1: I want to shout out to Pharma Staff for being
- 1:20Speaker 1: our support, for being an organization that gave us the
- 1:23Speaker 1: ability to go to Nashville and spend time with our
- 1:27Speaker 1: most favorite providers out there are pharmacists. And also a
- 1:30Speaker 1: shout out to your Ralph Pharma who was concentrating on
- 1:33Speaker 1: thyroid disease and pain management.
- 1:35Speaker 2: And a shout out to Mark GARYL. Foley, the pain Guy.
- 1:40Speaker 2: He's known as the pain Guy. He was there.
- 1:42Speaker 1: He's going to be part of the show. It's going
- 1:44Speaker 1: to be a great three part series. If you didn't
- 1:47Speaker 1: get to attend the APHA, it was busy, it was
- 1:51Speaker 1: a lot. It was a lot going on. There was
- 1:53Speaker 1: inspiration everywhere. That was the theme this year. But back
- 1:57Speaker 1: to our theme right now, the National ADS Drug Event
- 2:01Speaker 1: Awareness Day and how important that is specifically to our pharmacist.
- 2:06Speaker 1: Pharmacist the number one provider out there keeping patients safe.
- 2:10Speaker 1: And I have a very special guest has to be
- 2:13Speaker 1: a pharmacist. That's my favorite provider. And i'd like to
- 2:16Speaker 1: welcome to Twerks doctor Sarah Rodgers. Welcome to this Week
- 2:20Speaker 1: in Pharmacy.
- 2:21Speaker 3: Hey Todd, thanks so much for having me, and I
- 2:23Speaker 3: have to say I'm really looking forward to that three
- 2:25Speaker 3: part series.
- 2:26Speaker 4: For about the aph meeting.
- 2:28Speaker 1: Absolutely, it was a corner kopia of or i should
- 2:32Speaker 1: say polypharmacy of pharmacists and it was wonderful. It was
- 2:36Speaker 1: so good to be with people and it was relaxed,
- 2:39Speaker 1: and we were on the edge of the entire main booth.
- 2:43Speaker 1: So we run lane one and we got a ton
- 2:45Speaker 1: of traffic and lots of pharmacy students wanted to know
- 2:48Speaker 1: what we were doing. And what's fun about pharmacy students,
- 2:51Speaker 1: Sarah is I can give them a link to our
- 2:53Speaker 1: shows and they get forty podcasts they can access and
- 2:57Speaker 1: really think, you know what sector of pharmacy am I in?
- 3:00Speaker 2: Interested in? Pediatrics or jerity?
- 3:01Speaker 4: Yeah, it's like the supplemental education exactly.
- 3:06Speaker 1: Well, I'm glad you're here, doctor Sarah Rogers farm d
- 3:10Speaker 1: And before I get into the American Society of Pharma, collage,
- 3:13Speaker 1: pharma covigilance, I want to know why you wanted to
- 3:16Speaker 1: be a pharmacist.
- 3:18Speaker 3: That is a great question because I actually had quite
- 3:21Speaker 3: a journey before I landed on pharmacy. I came in
- 3:27Speaker 3: I wasn't maybe a business major, economics major.
- 3:31Speaker 5: Uh.
- 3:31Speaker 3: Then I kind of came drawn to the sciences. So
- 3:34Speaker 3: I transferred to the you know, School of Natural Sciences,
- 3:37Speaker 3: did biology, and as I was still kind of deciding
- 3:41Speaker 3: what I was going to do, maybe my junior year,
- 3:44Speaker 3: we had a really good family friend that was a
- 3:46Speaker 3: pharmacist and.
- 3:46Speaker 4: She just absolutely loved her job.
- 3:48Speaker 3: She worked in a hospital, and that's when I decided
- 3:53Speaker 3: to go to pharmacy school. So I almost feel like
- 3:58Speaker 3: it's just these different events kind guide you one direction.
- 4:02Speaker 3: I wasn't anything I had heard of before. I had
- 4:05Speaker 3: heard about it from a family frun So.
- 4:08Speaker 1: So how did your interest in really dialing into drug
- 4:17Speaker 1: awareness and adverse reactions and how that affects the public,
- 4:21Speaker 1: you know, public health and people. And because when I
- 4:24Speaker 1: think of pharmacists, that's the number one reason for pharmacists
- 4:27Speaker 1: make sure people aren't dying based on medications that may
- 4:30Speaker 1: either play not play well with something else that they're on,
- 4:34Speaker 1: or maybe they're allergic or something's going on. But this
- 4:37Speaker 1: whole pharmacovigilance is so fascinating to me. And we just celebrated,
- 4:43Speaker 1: you know, National Adverse Drug Event Awareness Day. So this
- 4:48Speaker 1: is a perfect twerks to have at the end of
- 4:50Speaker 1: a busy week.
- 4:52Speaker 6: Yeah.
- 4:52Speaker 3: Absolutely, And I will say kind of going through pharmacy school.
- 4:55Speaker 3: As much as it seems intuitive that pharmacists are the
- 4:58Speaker 3: ones that should be preventing adverse drug events and often are,
- 5:03Speaker 3: there's a few topics that aren't consistently covered in the
- 5:07Speaker 3: traditional farmde curriculum. Pharmaco vigilance is one of them. From
- 5:12Speaker 3: a drug safety perspective, Pharmacogenomics is another thing I didn't
- 5:16Speaker 3: learn about in pharmacy school. I was, I think more
- 5:19Speaker 3: and more it's getting incorporated, but genetic predisposition to drug response.
- 5:24Speaker 3: And when I left pharmacy school and when I worked
- 5:27Speaker 3: at M. D. Anderson, so I was in oncology for
- 5:29Speaker 3: a few years and it was actually a consulting opportunity
- 5:33Speaker 3: that I was working on where we're doing this research
- 5:36Speaker 3: and we found out that adverse drug events were a
- 5:39Speaker 3: leading cause of death.
- 5:41Speaker 4: And that was also.
- 5:42Speaker 3: Something that I didn't really fully realize when I was
- 5:45Speaker 3: going through pharmacy school. So it wasn't after until I
- 5:49Speaker 3: went out into you know, working, that I found out
- 5:56Speaker 3: what a tremendous problem this is. And so the person
- 6:01Speaker 3: I was working on this project with, his name is
- 6:02Speaker 3: Ben Brown, is also the co founder for ASP. We
- 6:06Speaker 3: kind of just looked around to see what organization was
- 6:09Speaker 3: specifically working on addressing the high rate of adverse drug
- 6:12Speaker 3: events in the US, and there are different medication safety organizations,
- 6:16Speaker 3: for example, Institute of Safe Medicine Practices, IMP there, they're
- 6:21Speaker 3: solely focused on preventing medication errors, which is one type
- 6:25Speaker 3: of adverse drug event, and so that's when we decided
- 6:29Speaker 3: to start ASP and we've really focused a lot on
- 6:33Speaker 3: another component of adverse drug events called adverse drug reactions.
- 6:37Speaker 3: So that's side effects from medications that are taken as
- 6:42Speaker 3: prescribed at typical doses, so not an overdose, not a mistake.
- 6:46Speaker 3: And there's a lot of variation in how people respond
- 6:49Speaker 3: to medications, and a lot of that is based on
- 6:51Speaker 3: differences in genetics.
- 6:52Speaker 4: So that's where a lot of our projects.
- 6:54Speaker 3: Have been around pharmacogenomics and precision medicine over the past
- 6:58Speaker 3: several years.
- 7:00Speaker 1: I'm glad you're here to talk about it and kind
- 7:01Speaker 1: of drill down into it. Because of recent report according
- 7:05Speaker 1: to Saint John Fisher University, there's approximately three point five
- 7:09Speaker 1: million physician visits, one million emergency department visits, and one
- 7:13Speaker 1: hundred and twenty five thousand hospital admissions each year based
- 7:18Speaker 1: on adverse drug reactions. So that's major. I mean, that's
- 7:21Speaker 1: something that must be paid attention to. And in the
- 7:25Speaker 1: first line of defense is that pharmacist that's really dialed
- 7:28Speaker 1: in can talk to me about the event. Talk to
- 7:32Speaker 1: me about what we just passed this week and the
- 7:35Speaker 1: attention that you're bringing, and then I obviously I'm gonna
- 7:37Speaker 1: have some additional follow up conversation or questions about the ASP.
- 7:43Speaker 4: Yeah, of course.
- 7:44Speaker 3: So in twenty twenty one, we had developed a social
- 7:49Speaker 3: media campaign called the Fourth Cause campaign to highlight adverse
- 7:54Speaker 3: drug events at the time, which were cited as a
- 7:57Speaker 3: fourth leading cause of death. And we're looking for a
- 8:01Speaker 3: meaningful day to launch this campaign. And I'll mention also
- 8:07Speaker 3: that we did put out a press release on Monday
- 8:09Speaker 3: that it's actually now higher than the fourth cause, so
- 8:14Speaker 3: it's the third cause of death with all things considered.
- 8:17Speaker 3: And we didn't see a national day, and there's a
- 8:21Speaker 3: lot of different national days, but there wasn't one that
- 8:24Speaker 3: we could find that was focused on adverse drug events.
- 8:27Speaker 3: So we put in a proposal to start National Adverse
- 8:34Speaker 3: Strug Event Awareness Day.
- 8:35Speaker 4: There's a couple of private.
- 8:38Speaker 3: Organizations that name national days. There can't be any other
- 8:43Speaker 3: day that focuses on the same topic. It has to
- 8:46Speaker 3: follow certain guidelines, it has to get unanimous approval by
- 8:49Speaker 3: a board. So we found out right before the first
- 8:53Speaker 3: ADYE Day in twenty twenty one that it was approved,
- 8:56Speaker 3: and that's when we launched the Fourth Cause campaign, which
- 8:59Speaker 3: now is being rebranded to third Cause to highlight the escalation.
- 9:04Speaker 4: And some of these events that have been happening.
- 9:07Speaker 2: That's exciting that the impact of pharmacists bringing the awareness
- 9:11Speaker 2: to this is now it's a national day. Why did
- 9:13Speaker 2: the national day become officiated?
- 9:18Speaker 3: I want to say it was February twenty twenty one,
- 9:21Speaker 3: so it gave us about a month month and a
- 9:23Speaker 3: half to prep for our official launch on March twenty
- 9:26Speaker 3: fourth and twenty twenty one, So we just held our
- 9:29Speaker 3: fourth annual one and each.
- 9:31Speaker 4: Year it grows.
- 9:33Speaker 3: We have this social media campaign where people can use
- 9:36Speaker 3: the hashtag fourth Cause or third Cause now to not
- 9:41Speaker 3: just healthcare professionals who we encourage to talk about what
- 9:45Speaker 3: they do to prevent adverse arguments, but also patients. So
- 9:48Speaker 3: we can understand that perspective of individuals and their loved
- 9:53Speaker 3: ones potentially who have had serious adverse reactions, and so
- 9:58Speaker 3: if anyone were to type in in the hashtag fourth Cause,
- 10:02Speaker 3: you can see some of those stories and it can
- 10:05Speaker 3: be sometimes very tragic. So it just helps bring national
- 10:09Speaker 3: attention to this issue, which I think is becoming more
- 10:13Speaker 3: and more at the forefront as head of Department of
- 10:16Speaker 3: Health and Human Services also came out a couple of
- 10:19Speaker 3: weeks ago and said adverse dry events or the third
- 10:22Speaker 3: leading cause of death now when it was originally the
- 10:26Speaker 3: fourth when we launched the campaign.
- 10:29Speaker 2: Wow.
- 10:30Speaker 1: So we also want to let your listeners and let
- 10:33Speaker 1: our listeners know that there is a conference this fall
- 10:38Speaker 1: October twenty third, twenty fifth.
- 10:41Speaker 2: Oh, this is last year's conference.
- 10:43Speaker 4: It was a great conference.
- 10:44Speaker 1: So Todd I was wondering, I'm hoping that we can
- 10:47Speaker 1: talk about a conference upcoming.
- 10:49Speaker 2: Do you have another one in October of twenty twenty five.
- 10:55Speaker 3: We were thinking of doing it every other year. That
- 10:58Speaker 3: was the first one we did. So that one was
- 11:02Speaker 3: a consensus development conference and we're going to and it
- 11:07Speaker 3: was at the United States Pharmacopeia, who are going to
- 11:10Speaker 3: be they're also launching a personally kind of like a
- 11:14Speaker 3: new USP standard for pharmacogenomics. So there is someone a
- 11:18Speaker 3: committee now and we're going to be working with them
- 11:20Speaker 3: to support standards development. But we are the consensus statements
- 11:27Speaker 3: that we developed during the conference are going to be
- 11:29Speaker 3: opened to the public for public comments, so and those
- 11:33Speaker 3: will be published in j accp.
- 11:36Speaker 1: Okay later this year the ASPS objectives on your website.
- 11:42Speaker 1: When I think of precision medicine and pharmacogenomics, I always,
- 11:46Speaker 1: of course have conspiracy theories as to why it's not
- 11:50Speaker 1: a fully blown usage science. And I hear from a
- 11:53Speaker 1: lot of intelligence people, intelligent people who's in pharmacogenomics as
- 11:58Speaker 1: to the reason. But once again my conspiracy theorist mind,
- 12:02Speaker 1: and I'm the consumer, so I get to act like that.
- 12:04Speaker 1: I don't have to come with evidence base per se,
- 12:07Speaker 1: and that is you know, there's pharma companies out there
- 12:10Speaker 1: who would be would be sued if pharmacogenomics became you know,
- 12:17Speaker 1: one hundred percent go effective. If we said, hey, wait
- 12:21Speaker 1: a second, there are fifty sixty seventy percent of the
- 12:26Speaker 1: people that are taking this medication are not able to
- 12:30Speaker 1: metabolize as designed, or not able to consume or not
- 12:33Speaker 1: or allergic to it or something. So what do you
- 12:37Speaker 1: think is some of your there's probably several roadblocks, but
- 12:41Speaker 1: what are some of the roadblocks you're thinking of why
- 12:44Speaker 1: PGX isn't like just natural part of testing like you
- 12:49Speaker 1: would take a you know, a strip test, you'd take
- 12:52Speaker 1: some other kind of you know, cheek swab test or
- 12:55Speaker 1: something like, what is it about PGX that you think
- 12:58Speaker 1: that that we still have these roadblocks.
- 13:02Speaker 3: It's a great question, and also I just love that
- 13:05Speaker 3: you're asking the question. That's what we really encourage people
- 13:07Speaker 3: to do is ask questions when it comes to your meds.
- 13:11Speaker 3: But with regard to challenges with PGX, a couple of things. So,
- 13:17Speaker 3: and you mentioned the pharmaceutical aspect of it, and there
- 13:21Speaker 3: is some kind of thoughts or hypotheses around is this
- 13:26Speaker 3: intentionally being blocked? But I will say FDA does have
- 13:32Speaker 3: guidance to drug companies that to do pharmacogenetics testing during trials,
- 13:40Speaker 3: but it's optional, it's not enforced if you will, it's
- 13:43Speaker 3: just a recommendation. So that's one piece of it, but
- 13:47Speaker 3: it is good. They do recommend collecting the sample so
- 13:50Speaker 3: if anything comes up in post marketing surveillance, they can
- 13:53Speaker 3: go back and see what's there's something PGX related. And
- 13:57Speaker 3: there are several medications that do have information in the
- 14:03Speaker 3: drug label that either recommends or requires testing. We like
- 14:07Speaker 3: to see more guidance like that of the requiring testing
- 14:11Speaker 3: portion of it, and then how that information from the
- 14:16Speaker 3: drug label gets translated into clinical practice guidelines. Is another challenge.
- 14:22Speaker 3: So we actually reviewed dozens and dozens of clinical practice
- 14:26Speaker 3: guidelines basically any guideline that has a drug with a
- 14:31Speaker 3: known pharmacogenetic association, and there was a lot of I
- 14:36Speaker 3: think gaps in the guidelines compared with the evidence. And
- 14:40Speaker 3: then there was also discrepancies between different guidelines that reference
- 14:46Speaker 3: the same medication, So it might be recommended in one
- 14:49Speaker 3: guideline for that medication, but the same medication and a
- 14:52Speaker 3: different guideline may not mention PGX at all. So those
- 14:56Speaker 3: are some of the challenges and I think with so
- 14:59Speaker 3: many guidelines developing groups and there's some questions around how
- 15:04Speaker 3: those decisions are made, which we haven't gotten a lot
- 15:08Speaker 3: of clarity on UH. And then of course the reimbursing
- 15:13Speaker 3: the cost of testing is another big one. We just
- 15:16Speaker 3: looked at a lot of the medical policies for pharmacogenetic
- 15:20Speaker 3: testing and we published that in a j MC is
- 15:23Speaker 3: a paper by J.
- 15:26Speaker 4: Patel at all.
- 15:28Speaker 3: But we looked at the top ten payers based on
- 15:30Speaker 3: number of covered lives to see if pharmacogenetics was covered
- 15:36Speaker 3: and then what was that evidence used to determine, you know,
- 15:40Speaker 3: that recommendation either covering the testing or not covering the testing.
- 15:45Speaker 3: So I will say a lot of payers do actually
- 15:48Speaker 3: cover pharmacogenetics testing, just not necessarily that panel preemptive testing
- 15:53Speaker 3: like what you describe. Why can't everyone just get a
- 15:55Speaker 3: swab and we can know and then that can be
- 15:58Speaker 3: used for all of our you know, if you sure
- 16:00Speaker 3: prescribing decisions. So I think those are a couple of
- 16:06Speaker 3: the key challenges. But honestly, I think the biggest challenges
- 16:10Speaker 3: we face with integrating PGX testing at the point of care.
- 16:15Speaker 3: Our challenges are just really logistical challenges and workflow and
- 16:21Speaker 3: you know, getting that information into the EHR and some
- 16:25Speaker 3: of those kind of frontlines challenges which we're also dealing
- 16:30Speaker 3: with in the clinic.
- 16:31Speaker 1: Too, yes, and letting the public know that the test
- 16:37Speaker 1: is available, and if there are medications that they're on
- 16:41Speaker 1: that are the top one hundred, you know, medications that
- 16:47Speaker 1: go over a specific percentage of people that are having issues,
- 16:52Speaker 1: you know with whatever metabolization or allergic reaction or something,
- 16:56Speaker 1: that they know that The first time I was ever
- 16:59Speaker 1: introduce used to pharmacogenomics, it wasn't even a pharmacist that
- 17:03Speaker 1: introduced it to me. It was an entrepreneur out of Greensburg,
- 17:06Speaker 1: Pennsylvania near Pittsburgh.
- 17:08Speaker 2: His name is Dom Mef and he since passed away.
- 17:12Speaker 1: But when he introduced me to it, he was trying
- 17:15Speaker 1: to build an application that would connect to the EHR
- 17:18Speaker 1: system that UPMC in Pittsburgh was using and then quickly
- 17:22Speaker 1: help the physician know if it was a candidate for
- 17:27Speaker 1: the test based on CPT and ICD ten codes if
- 17:32Speaker 1: it were, if it was candidate to be reimbursed, and
- 17:35Speaker 1: then he sold that application too.
- 17:37Speaker 2: I think UPMC enterprises.
- 17:39Speaker 1: But what was interesting about his own experience is he
- 17:46Speaker 1: wasn't able to metabolize a blood thinner that he was
- 17:50Speaker 1: on and it caused him issues during one of his surgeries.
- 17:53Speaker 1: So he would bring his PGX test. He made a
- 17:58Speaker 1: booklet and he had laminated and it was like thick
- 18:02Speaker 1: and it had almost every medication that he purposely paid himself.
- 18:07Speaker 2: He paid for the lab to do all the testing
- 18:10Speaker 2: on all the panels.
- 18:11Speaker 1: Your physician and say, listen, you were not giving me
- 18:15Speaker 1: any medications. I'm not getting on the operating room table
- 18:18Speaker 1: until you go through this. And that's back in like
- 18:21Speaker 1: twenty twelve, thirteen fourteen, when testing was like twenty one
- 18:26Speaker 1: hundred dollars for panel today, it's drastically less expensive, but
- 18:32Speaker 1: nonetheless it's a life savings test and I just want
- 18:35Speaker 1: to see it, you know, come to full usage and
- 18:40Speaker 1: being able to get the consumers to understand that, hey,
- 18:44Speaker 1: your DNA is different than your moms, different than your aunt,
- 18:47Speaker 1: different than your friends, and just because this medication is
- 18:50Speaker 1: working on them, doesn't mean it's necessarily working on you.
- 18:54Speaker 1: Make sure that you get tested so that you know
- 18:56Speaker 1: that if you are on a bunch of medications, that
- 19:00Speaker 1: that they're working as intended.
- 19:02Speaker 3: I will say that's one of the most fascinating things
- 19:05Speaker 3: over the past few years is the response from people
- 19:08Speaker 3: when we tell them about pharmacogenetics testing. Actually, I do
- 19:14Speaker 3: this talk called Safe Medication Management for Seniors, and there's
- 19:19Speaker 3: a big conference that it's not a health or medication
- 19:23Speaker 3: related conference, but it's for older adults and they do
- 19:28Speaker 3: yoga and things like that, and they asked me to
- 19:30Speaker 3: come in to do my safe Safe med Management for
- 19:33Speaker 3: Seniors talk and I just gave them some tips using
- 19:35Speaker 3: a pillbox, things like that, and at the very end,
- 19:38Speaker 3: almost as kind of like and off the on the
- 19:42Speaker 3: flight kind of mention, I talked about pharmacogenetics testing we're
- 19:48Speaker 3: doing this conference of Medication Management Service at Texas and
- 19:51Speaker 3: m Health where I work, and we do this type
- 19:54Speaker 3: of genetic testing that lets you know more about how
- 19:57Speaker 3: you respond to medications. And you would not believe the
- 20:00Speaker 3: queue of people just almost all the way to the
- 20:04Speaker 3: back of the room asking if they could, you know,
- 20:07Speaker 3: participate in in that service, which we first launched as
- 20:12Speaker 3: a research pilot. They're like, you know, I live in
- 20:14Speaker 3: this totally other area of the state, but I'll drive
- 20:16Speaker 3: in for that. And you know, I always thought kind
- 20:21Speaker 3: of for Medicare enrolies, they do a Medicare annual wellness
- 20:25Speaker 3: visit and that's when they're supposed to go through your
- 20:28Speaker 3: primary care physician goes through and looks at all your meds.
- 20:31Speaker 3: And at the time, I made a comment on one
- 20:34Speaker 3: of the guest attendees about that and she's like, no,
- 20:37Speaker 3: I just had a wellness visit, they didn't look at
- 20:39Speaker 3: my meds. So I think that really is in need
- 20:42Speaker 3: for pharmacists to have that chance to go in and
- 20:45Speaker 3: do that comprehensive medication management review and then if we
- 20:48Speaker 3: can add in the genetics information, that really adds a
- 20:52Speaker 3: lot of.
- 20:53Speaker 2: Value to it.
- 20:54Speaker 1: So absolutely, absolutely so also this week we had some
- 21:00Speaker 1: In my opinion, it was bad news because I don't
- 21:02Speaker 1: like to see companies that are in genetics, you know Falter,
- 21:07Speaker 1: but twenty me they filed for bankruptcy, and once again,
- 21:12Speaker 1: I don't think that's good for the consumer initiative of
- 21:16Speaker 1: understanding how important.
- 21:18Speaker 2: Your genes are and how you're.
- 21:20Speaker 1: You're affected by the foods you eat or by the
- 21:23Speaker 1: medications that you're taking. But yeah, that that was an
- 21:27Speaker 1: unfortunate thing that happened this week.
- 21:30Speaker 4: I read a little bit about that.
- 21:32Speaker 3: Do you I don't know, Todd, if you read more
- 21:34Speaker 3: than me kind of what were the factors at play
- 21:36Speaker 3: behind that?
- 21:39Speaker 2: Yeah, I agree with you.
- 21:40Speaker 4: I mean it's I think.
- 21:41Speaker 1: It's part of the woman that that started it, and
- 21:45Speaker 1: she did a full video about how this kind of
- 21:49Speaker 1: started happening. It actually started to crumble about five years
- 21:53Speaker 1: ago with the fact that their business model from the
- 21:56Speaker 1: very beginning required their consumer to take the test once
- 22:01Speaker 1: and that's it. So the reoccurring revenue build up and
- 22:05Speaker 1: they came up with an app that they wanted their
- 22:07Speaker 1: patients to stay engaged with and they try to you know,
- 22:11Speaker 1: change kind of the pricing model.
- 22:13Speaker 2: But that was probably the major issue was the.
- 22:16Speaker 1: Fact that you could take this test one time and
- 22:19Speaker 1: have you know, genetic information, and twenty three and meters
- 22:23Speaker 1: stopped doing the health side of things, and they were
- 22:25Speaker 1: they're really concentrating more on the ancestry, but they were
- 22:28Speaker 1: trying to help with drug development and data collect So
- 22:32Speaker 1: I don't know all the details of it. I'm going
- 22:34Speaker 1: to continue to read on it because I think, once again,
- 22:36Speaker 1: that's a fascinating organization, but that's a punch in the
- 22:39Speaker 1: eye when it comes to the genetic world. You know,
- 22:43Speaker 1: we don't want organizations like twenty three and meters who
- 22:46Speaker 1: have reached to the public. We don't want them failing
- 22:49Speaker 1: because we want genetics to come full circle of what
- 22:52Speaker 1: it could really empower pharmacists, physicians, research, drug development. And
- 22:57Speaker 1: I just think it's in the best interest of public
- 23:01Speaker 1: health to have an organization like twenty three and ME
- 23:04Speaker 1: doing very well instead of filing for bankruptcy.
- 23:08Speaker 6: Yeah.
- 23:09Speaker 3: Interesting, So it sounds like kind of a business model oversight,
- 23:15Speaker 3: But yeah, I think that's maybe where the business model
- 23:20Speaker 3: is is that when we use the PGX piece of
- 23:23Speaker 3: the genetic testing for med management, there's always going to
- 23:26Speaker 3: be changes to people's chronic conditions and what meds are taking.
- 23:31Speaker 3: So it's almost more of something that needs to be
- 23:33Speaker 3: consistently monitored. And it would be nice to have kind
- 23:38Speaker 3: of an enduring if twenty three and me even could
- 23:41Speaker 3: have had an enduring model like that, where it could
- 23:44Speaker 3: continue to provide.
- 23:45Speaker 4: Some health benefit.
- 23:48Speaker 3: But I think one of the challenges with twenty three
- 23:50Speaker 3: and me is that they specifically marketed it for kind
- 23:55Speaker 3: of informational purposes or almost for entertainment purposes kind of thing,
- 23:59Speaker 3: so that it didn't have to originally go through some
- 24:01Speaker 3: of those regulatory pathways that a lot of the PGX
- 24:06Speaker 3: tests go through in order to be you know, approved
- 24:11Speaker 3: or be able to use clinically at the point of care.
- 24:14Speaker 4: So that may be another oversight.
- 24:17Speaker 1: Yeah, there's going to be a day in our life's lifetime.
- 24:21Speaker 1: I know it that we will have an app on
- 24:24Speaker 1: our phones. We will take our phone to the grocery store.
- 24:28Speaker 1: We will walk up to a can of tomato sauce,
- 24:31Speaker 1: we will scan the tomato sauce, we will look at
- 24:34Speaker 1: the app, and we'll see how effective that that ingredient
- 24:40Speaker 1: is to our biological makeup and our DNA makeup, and
- 24:43Speaker 1: then go to an over countermed scan the med you know,
- 24:46Speaker 1: by barcode.
- 24:47Speaker 2: Look at the results.
- 24:49Speaker 1: Should I take this and it'll be colored red, yellow, orange, green?
- 24:53Speaker 2: And then if it's in the green, I can go
- 24:55Speaker 2: get it. If it's if it's.
- 24:56Speaker 1: Orange or red, you know, red or orange or yellow,
- 25:00Speaker 1: should contact my physician or contact my pharmacist. But there's
- 25:03Speaker 1: going to be an app someday that's going to allow
- 25:05Speaker 1: the consumer to constantly double check, especially if they're on
- 25:10Speaker 1: a lot of medications.
- 25:11Speaker 2: Is this going to interact? Is this going to interact?
- 25:13Speaker 1: Because we have so much data and we have so
- 25:16Speaker 1: much capability of involving genetics into foods and of course
- 25:21Speaker 1: our medications. But I'll believe I'm a science fiction guy,
- 25:25Speaker 1: so I know that that's going to come someday.
- 25:28Speaker 7: I mean, you're giving away all your hot business ideas,
- 25:31Speaker 7: and like on the podcast episode, that's why everyone needs
- 25:35Speaker 7: to subscribe to the Pharmacy Podcast Network so we can
- 25:37Speaker 7: get more hot business ideas like this.
- 25:39Speaker 3: But yeah, I think we let's do it. We have
- 25:42Speaker 3: the team here, podcast hosts, so.
- 25:47Speaker 1: Let's get them all together and we'll pound out the
- 25:50Speaker 1: PGX app for the consumer.
- 25:53Speaker 4: I like it, and then including the food relationships too.
- 25:59Speaker 1: Yeah, if you're allergic to something and you took a
- 26:02Speaker 1: cheek swab and now you have nutrient genomics intertwining with
- 26:05Speaker 1: pharmaca genomics, and that's how I'd want to live. I'd
- 26:08Speaker 1: want to know what I should be eating and what
- 26:09Speaker 1: I shouldn't be taking and drinking.
- 26:12Speaker 2: And everybody that continues to drink.
- 26:15Speaker 1: Some kind of alcohol, they'll be like, I'm just going
- 26:18Speaker 1: to ignore it. It's in the red and I'm just
- 26:20Speaker 1: going to keep buying this whatever you have. But at
- 26:23Speaker 1: least you could probably tie that to legalities too and
- 26:28Speaker 1: saying listen, and we know you took the test, we
- 26:30Speaker 1: know you have the app, and as a matter of fact,
- 26:32Speaker 1: you scanned that Jack Daniels, and you kept drinking it.
- 26:35Speaker 1: So now that you are suffering with cirrhosis, we're not
- 26:38Speaker 1: covering it, and insurances could even get involved.
- 26:42Speaker 3: Yeah, it's almost like an informed consent for just food
- 26:45Speaker 3: and drink consumption and over the counter medications and other
- 26:49Speaker 3: things that are all processed through the same metabolic pathways.
- 26:52Speaker 4: So now we're getting into pheno conversion.
- 26:55Speaker 1: I don't even know how to say that, but that's
- 26:57Speaker 1: why I have you here. Sarah Rodgers. This has been
- 27:01Speaker 1: awesome to talk with you. I want to just give
- 27:04Speaker 1: a shout out to our listeners. If you want to
- 27:06Speaker 1: connect with doctor Sarah Rodgers, please go to LinkedIn search
- 27:09Speaker 1: Sarah Rodgers. It does come right up. Pharmacist researcher, director
- 27:13Speaker 1: of Translating Genomics into improve patient Care. One of my
- 27:17Speaker 1: heroes is one of my favorite providers, Sarah. So I
- 27:20Speaker 1: hope to have you back on This Week in Pharmacy.
- 27:22Speaker 4: Oh well, thanks so much. It's been a pleasure. Always
- 27:24Speaker 4: good to chat with you.
- 27:36Speaker 8: This episode is sponsored by Independent Pharmacy Cooperative, widely known
- 27:40Speaker 8: as IPC. Established in nineteen eighty three, IPC is the
- 27:43Speaker 8: nation's largest group purchasing organization owned by independent pharmacy with
- 27:48Speaker 8: a mission of maximizing the success of community pharmacists. IPC
- 27:52Speaker 8: works to provide members with access to effective programs and
- 27:55Speaker 8: services designed to enhance profitability for independent pharmacy. Need more
- 28:00Speaker 8: about our mission by checking out our website at ipcrx
- 28:03Speaker 8: dot com. That's ipcrx dot com.
- 28:19Speaker 1: Hey, and on this Week in Pharmacy. Something that just
- 28:23Speaker 1: hit the news. Not sure if you've seen this. This
- 28:25Speaker 1: is important for our pharmacist out there, especially our consultant pharmacist,
- 28:29Speaker 1: and I think of our community pharmacist. I think of
- 28:32Speaker 1: our pure consultant pharmacist. But Noom NOM, I hope I'm
- 28:39Speaker 1: seeing that right. NOOM introduces hormone Replacement Therapy for Menopause Care,
- 28:45Speaker 1: and it goes into how NOOM is going to start
- 28:48Speaker 1: really drilling down into support for women experiencing menopause related
- 28:52Speaker 1: healthcare challenges, and this new service aims to address gaps
- 28:56Speaker 1: in menopause care as only thirty percent of women seeking
- 28:59Speaker 1: treatment receive adequate support. NEWM goes on to saying that
- 29:03Speaker 1: already they've guided eight million women aged forty to sixty
- 29:08Speaker 1: through its behavioral based weight management program, and how many
- 29:13Speaker 1: of those women have reported difficulties in their health and
- 29:16Speaker 1: weight loss due to metapause symptoms. You know this is
- 29:20Speaker 1: important to me because I think of opportunities to bring
- 29:23Speaker 1: pharmacists to our programs into this week in pharmacy, who
- 29:27Speaker 1: really dial into specific issues that we know that your
- 29:31Speaker 1: patients out there in community, in geriatrics, in specialty pharmacy
- 29:36Speaker 1: are actually experiencing. And with pharmacists being seen nine times
- 29:40Speaker 1: more per year than the physician, it's the reason that
- 29:44Speaker 1: this network continues to get powerful and supporting pharmacists out
- 29:49Speaker 1: there who love their patients want to help their patients.
- 29:52Speaker 1: I'd like to introduce my special guests, doctor to Tiffany
- 29:56Speaker 1: Ruter to this Week in Pharmacy.
- 30:00Speaker 6: Hi, Toad, thank you for the introduction.
- 30:02Speaker 1: Absolutely, and I don't know if you saw that, but
- 30:05Speaker 1: NEOM is really hitting hard with this hormone replacement therapy
- 30:10Speaker 1: for women that are experiencing menopause. And you and I
- 30:13Speaker 1: have talked about this issue. You advocate for this issue,
- 30:16Speaker 1: you have an amazing Facebook following and presence with your consultancy,
- 30:21Speaker 1: So what do you think of this?
- 30:23Speaker 2: As much as I like to.
- 30:24Speaker 1: Hear about it, I get worried that the patient's going
- 30:28Speaker 1: to get lost in the gargantuan movement of somebody like
- 30:33Speaker 1: NOOM who's focused on a whole bunch of different disease states.
- 30:36Speaker 1: Where you really have a vertical that's very special. So
- 30:40Speaker 1: share with our listeners what doctor Ruter is doing in
- 30:43Speaker 1: that space.
- 30:44Speaker 2: Sure.
- 30:45Speaker 5: So, I'm the founder of Better Health and Hormone Balance Ills,
- 30:49Speaker 5: and I work with midlife women one on one to
- 30:52Speaker 5: help them balance their health and their hormones so they
- 30:55Speaker 5: can just live radiantly.
- 30:56Speaker 6: Restored lives.
- 30:58Speaker 5: When you get an opportunity, especially as a pharmacist or
- 31:00Speaker 5: even in the community setting, you do find that you
- 31:03Speaker 5: have a lot of contact with those clients and you
- 31:06Speaker 5: get to hear their stories, and you get to understand
- 31:09Speaker 5: their lifestyle, and you really get to understand the heart
- 31:13Speaker 5: of the issues that they're going through. And I think
- 31:16Speaker 5: from an pharmacist standpoint, I just recognize there was such
- 31:18Speaker 5: a large opportunity to work with women to really hear
- 31:22Speaker 5: their stories, to advocate for them and then validate what
- 31:25Speaker 5: they're experiencing, and then find them the solutions to their issues.
- 31:30Speaker 6: Right, So that is our whole the journey that.
- 31:32Speaker 5: I have gone down is that I love helping women
- 31:36Speaker 5: work with their lifestyle, work with those small changes that
- 31:39Speaker 5: are going to add up to big results so they
- 31:41Speaker 5: can feel their best each and every day. There are
- 31:44Speaker 5: a lot of demands, whether it's motherhood or your employee,
- 31:48Speaker 5: maybe you have a spouse, maybe you have aging parents. Like,
- 31:51Speaker 5: there's a lot of demands that go on throughout the day,
- 31:54Speaker 5: and when you're not feeling your best, when you're having
- 31:57Speaker 5: not hot flashes or night sweats, if you're not sleeping
- 32:00Speaker 5: at night, if you're irritable or moody. You can't perform
- 32:03Speaker 5: your best and you can't live your best life when
- 32:05Speaker 5: you look when you feel that way. So I work
- 32:09Speaker 5: with these women to help find those solutions so they
- 32:13Speaker 5: can reverse those symptoms, so we can really address those
- 32:15Speaker 5: root causes of why they're feeling that way. From a
- 32:19Speaker 5: community pharmacy standpoint, it's such an excellent way to capture
- 32:23Speaker 5: and talk to those women that are coming into your pharmacy.
- 32:26Speaker 5: So there's a lot of opportunity because they do have
- 32:28Speaker 5: a story to share, they do have a journey that
- 32:30Speaker 5: they're going through, and through consultation, you can carve out
- 32:34Speaker 5: that time to really sit with them, hear their story,
- 32:38Speaker 5: validate their symptoms, and then help them find those solutions.
- 32:41Speaker 5: So with a company like NOOM, it's fantastic because they're
- 32:44Speaker 5: getting that bioidentical.
- 32:46Speaker 6: Hormone replacement therapy that they need.
- 32:49Speaker 5: But a pharmacists can really support and advocate for that
- 32:53Speaker 5: patient while they're on that therapy because they're gonna need
- 32:56Speaker 5: they're gonna have questions, and they're gonna need someone that
- 32:59Speaker 5: has the knowledge base that pharmacists have to support them
- 33:04Speaker 5: through that journey. And I think it's such an excellent
- 33:06Speaker 5: opportunity for that pharmacist to really become kind of like
- 33:10Speaker 5: the point of a triangle between the patient, the physician,
- 33:13Speaker 5: and then you as a pharmacist that you can be
- 33:16Speaker 5: that advocate, You can work with them one on one.
- 33:20Speaker 5: You have those opportunities to really support them and honestly
- 33:23Speaker 5: just make a big impact in their life. Because every woman,
- 33:27Speaker 5: if they live long enough, will go through menopause.
- 33:30Speaker 6: So this isn't something that's optionable optional for women.
- 33:33Speaker 5: We're going to go through it, and so we need
- 33:35Speaker 5: someone in our corner that's going to support us. And
- 33:38Speaker 5: so that's my hor motto is I've stepped out from
- 33:40Speaker 5: behind the pharmacy counter. I'm stepping into your corner to
- 33:44Speaker 5: help you live radiantly restored.
- 33:46Speaker 1: I love that, Tiffany, and there's so much positivity to it,
- 33:50Speaker 1: and there's guidance to it. Our physicians out there, God
- 33:53Speaker 1: bless them, are so pounded and overwhelmed with so many patients.
- 33:59Speaker 1: And yes, even my own physician, he is wonderful. He's
- 34:04Speaker 1: second generation. I was with his father. His father passed away.
- 34:09Speaker 1: He took over, which I thought was kind of special,
- 34:11Speaker 1: and now he continues to drive quality. But he even
- 34:17Speaker 1: he that he doesn't think he gets enough attention with
- 34:20Speaker 1: some of his patients who are high touch, who need
- 34:23Speaker 1: more attention. And I think this hormone replacement is definitely
- 34:28Speaker 1: one of those subjects where you want to talk to
- 34:31Speaker 1: somebody who knows what they're talking about, who can guide you,
- 34:34Speaker 1: who can even make suggestion for supplements along the way,
- 34:37Speaker 1: maybe stages of therapy, maybe dosing challenges or adjustments in dosing.
- 34:43Speaker 1: So if the football is handed off to the pharmacist
- 34:46Speaker 1: in this realm, then the pharmacist and the patient can
- 34:50Speaker 1: drive things and then communicate back to the physician how
- 34:53Speaker 1: things are going or making some suggestions right out of
- 34:56Speaker 1: the gate. What's your suggestion to pharmacists listening, whether they
- 35:00Speaker 1: own their own community pharmacy or whether they're a consultant
- 35:03Speaker 1: pharmacy like pharmacists like you, what do we do we
- 35:07Speaker 1: talk with the patient. Let's say we're talking to a woman.
- 35:10Speaker 1: She's fifty eight years old, she's experiencing hot flashes, she's
- 35:13Speaker 1: kind of going through the first stages of metopause. We
- 35:16Speaker 1: could say to her, hey, reach out to your physician.
- 35:20Speaker 1: Let them know that you have a pharmacist in your
- 35:22Speaker 1: corner who specializes in hormone replacement therapy. Maybe give them
- 35:27Speaker 1: this PDF or give them this form so that they
- 35:29Speaker 1: know what we're talking about. How do we kind of
- 35:32Speaker 1: reverse the system because we know we need a prescription,
- 35:35Speaker 1: we know we need physician involvement, but sometimes a physician
- 35:38Speaker 1: almost needs guidance to get to the next stage based
- 35:41Speaker 1: on the intelligence of a pharmacist. So kind of demystify
- 35:44Speaker 1: that for.
- 35:44Speaker 6: Us for sure.
- 35:46Speaker 5: I mean, it definitely starts with that interaction with the
- 35:48Speaker 5: patient in knowing that they are looking for those answers.
- 35:51Speaker 5: A lot of pharmacies can even work with collaborative agreements
- 35:55Speaker 5: with a physician, So sometimes it may not be the
- 35:58Speaker 5: physician directly that you get in contact with. You might
- 36:01Speaker 5: need to talk to maybe an office manager. But I
- 36:04Speaker 5: would give them some of your pharmacy information, who you are,
- 36:08Speaker 5: what you do, how you specialize in this area. And
- 36:11Speaker 5: then also, because like all of us pharmacists, we love
- 36:15Speaker 5: evidence based information, maybe send over a few research you know,
- 36:21Speaker 5: a few studies and even not just case studies about
- 36:24Speaker 5: hormone replacement therapy, but send them over some studies about
- 36:27Speaker 5: how having a pharmacist in your practice or working alongside
- 36:32Speaker 5: you actually increases patient adherence and patient outcomes. So it's
- 36:37Speaker 5: definitely a win win for the physician when they know
- 36:40Speaker 5: that you are stepping into their corner to support them
- 36:43Speaker 5: as well. You're not stepping on toes, you're stepping alongside
- 36:47Speaker 5: them to help them get the best outcomes for this patient.
- 36:51Speaker 5: So just really having that mentality of collaboration of support,
- 36:56Speaker 5: give them the evidence because everyone likes to have that
- 36:59Speaker 5: hard data of how you're going to support this patient,
- 37:02Speaker 5: and then you can work from there on what the
- 37:04Speaker 5: best next steps are. Sometimes it is just small lifestyle modifications,
- 37:09Speaker 5: but sometimes we do need to add in a medication
- 37:11Speaker 5: of bioidentical hormone just to start alleviating those symptoms, starting
- 37:16Speaker 5: to get them a little bit more regulated in the
- 37:18Speaker 5: hormone journey. While you as a pharmacist, with the regular
- 37:22Speaker 5: interaction you're going to have with that patient, then you
- 37:25Speaker 5: can set up other consultations with that patient to address
- 37:29Speaker 5: lifestyle modifications. Maybe it's stress management, maybe it's sleep, Maybe
- 37:33Speaker 5: they need a supplement. Maybe we're looking at some nutritional
- 37:36Speaker 5: deficiencies that are really ramping up those hormone issues, So
- 37:40Speaker 5: then we can also talk about supplementation.
- 37:42Speaker 6: You can work that into your practice as well.
- 37:44Speaker 5: Then with all of that, you can send all that
- 37:47Speaker 5: as a summary not only to the patient, but to
- 37:50Speaker 5: the physician as well. So now the prescriber knows, Okay,
- 37:54Speaker 5: this pharmacist is really invested in my patient and they're
- 37:57Speaker 5: really going to take care of them.
- 37:59Speaker 6: And it built what's that trust? And we are you know,
- 38:02Speaker 6: we have so much knowledge.
- 38:04Speaker 5: Pharmacists, I think sometimes are unrecognized for how much we
- 38:07Speaker 5: know about pharmacology, about biochemistry, and it really gives us
- 38:12Speaker 5: a chance to show up and shine and say, hey,
- 38:15Speaker 5: I'm going to help you take care of your patient.
- 38:16Speaker 5: I'm going to be an advocate for them for the
- 38:19Speaker 5: best care, and this.
- 38:20Speaker 6: Is how I'm going to do it.
- 38:21Speaker 1: All right, let's shift gears and talk about the market.
- 38:24Speaker 1: The market is hot, so listen. We just found a
- 38:29Speaker 1: news article that was posted just this week. Open PR
- 38:34Speaker 1: Worldwide Public Relations just put out a story aging population
- 38:38Speaker 1: and health awareness fuel the HRTAM market. The hormone replacement
- 38:43Speaker 1: therapy market is set to grow at an estimate of
- 38:47Speaker 1: five point yeah five percent from twenty twenty five to
- 38:52Speaker 1: twenty thirty four, rising from twenty five billion to forty
- 38:56Speaker 1: billion by twenty thirty four. That tells me, Tiffany, is
- 39:01Speaker 1: that this is not a space that is shrinking.
- 39:05Speaker 2: This is a space growing.
- 39:06Speaker 1: And if you're a consultant pharmacist and you can have
- 39:09Speaker 1: an entire bucket of services that you become an expert in,
- 39:13Speaker 1: and if this is one of those services, this is
- 39:16Speaker 1: a great sector of women's health that is one of
- 39:22Speaker 1: the sectors. I think that's on fire based on this data.
- 39:25Speaker 1: But what do you think of that? I mean that
- 39:26Speaker 1: for someone like you, that's got to be a good news.
- 39:30Speaker 6: It's really great news.
- 39:31Speaker 5: It also gives me just a little bit of hesitation
- 39:34Speaker 5: just of how many people are going to start trying
- 39:37Speaker 5: to get a piece of the pie that maybe aren't skilled.
- 39:42Speaker 5: So there is yeah, yeah, so you know, there's going
- 39:45Speaker 5: to be the influencers out there that might be having
- 39:48Speaker 5: this information. Maybe they're not reading those evidence based research
- 39:53Speaker 5: studies that all of us pharmacists like to read. So
- 39:56Speaker 5: I think it's a really I think it's an exciting time.
- 39:59Speaker 5: I think I'm just so excited or finally having a
- 40:01Speaker 5: conversation that's productive for women's care, that we're giving a
- 40:06Speaker 5: voice to the silent that have been silenced for a
- 40:08Speaker 5: very long time, and I think as pharmacists, this is
- 40:12Speaker 5: such a great time to take a stand and say
- 40:16Speaker 5: I am the knowledge expert in this field. You can
- 40:19Speaker 5: trust me, and I am going to work with you
- 40:21Speaker 5: and advocate for you, as opposed to you know, the
- 40:24Speaker 5: influencer on social media that's getting all these followers, but
- 40:28Speaker 5: their information is misguided and it's misled, And I don't
- 40:31Speaker 5: want other women to get misled or misguided. I want
- 40:34Speaker 5: them to have all the information so they can make
- 40:37Speaker 5: the most informed decision regarding their health. So, as a pharmacist,
- 40:42Speaker 5: like this is a time for you to go ahead
- 40:44Speaker 5: and find you know, find that passion, find that niche,
- 40:47Speaker 5: and if it's in hormones, definitely take advantage of it,
- 40:50Speaker 5: because this is a great time to really advocate for
- 40:52Speaker 5: your patient, make a difference in their lives, and really
- 40:55Speaker 5: help build a healthier generation of women and help build
- 40:59Speaker 5: a healthier your community in your surroundings.
- 41:03Speaker 1: Doctor Tiffany Ruter, you have to promise that you'll come
- 41:05Speaker 1: back and we'll maybe do a mashup with another pharmacist
- 41:09Speaker 1: who digs into women's health. Specifically, we have three or
- 41:12Speaker 1: four shows on the network that focus on women's health
- 41:15Speaker 1: so we'll have to get you introduced to Marino Boskov
- 41:20Speaker 1: and Daniel Plummer who really drive specific issues. But bioidentical
- 41:25Speaker 1: hormone therapy, hormone replacement therapy and the guidance of a
- 41:28Speaker 1: pharmacist is a win win win for people that are
- 41:32Speaker 1: out there that are concerned with it, and the guidance
- 41:34Speaker 1: that will provide is golden. So thank you so much
- 41:38Speaker 1: for being on this Week in Pharmacy.
- 41:40Speaker 6: Thank you so much for having me with such a pleasure.
- 41:43Speaker 2: Hey, before we go, how do people reach out to you?
- 41:46Speaker 6: Oh, you can find me on Facebook. I'm Tiffany Ruter.
- 41:49Speaker 6: I have an active Facebook.
- 41:51Speaker 5: This is where I'm hanging out most of the time,
- 41:53Speaker 5: and if you would are interested, I have a private
- 41:56Speaker 5: Facebook group it's called to Optimize Her. That is where
- 41:59Speaker 5: I provide education, support, advocacy. I know I put in a.
- 42:04Speaker 6: Lot of comments.
- 42:04Speaker 5: I'll do Facebook lives, so that's where you're really going
- 42:07Speaker 5: to a chance to interact with me, and then you
- 42:08Speaker 5: can also just find me on Facebook as Tiffany Ruter.
- 42:11Speaker 6: So thank you so much.
- 42:12Speaker 5: I'm excited to meet everyone, and thank you so much
- 42:15Speaker 5: for the opportunity to be here and share with you.
- 42:16Speaker 6: Today.
- 42:17Speaker 2: Thank you. We'll talk to you soon on this weekend.
- 42:20Speaker 2: Thank you.